Shattuck Labs Stock Price

0.05 (0.72%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 366,319
Bid Price 4.46
Ask Price 44.00
News -
Day High 7.16


52 Week Range


Day Low 6.73
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Shattuck Labs Inc STTK NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.05 0.72% 6.96 20:00:00
Open Price Low Price High Price Close Price Prev Close
6.73 6.73 7.16 6.96 6.91
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
3,695 366,319 $ 6.92 $ 2,534,898 - 6.66 - 59.5699
Last Trade Time Type Quantity Stock Price Currency
16:01:21 formt 503 $ 6.96 USD


Draw Mode:

Shattuck Labs Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 294.04M 42.25M 22.92M $ 9.93M $ - -2.53 -2.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -22.53k 1.70%

more financials information »

Shattuck Labs News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical STTK Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week7.127.506.666.93191,289-0.16-2.25%
1 Month8.969.466.667.69154,721-2.00-22.32%
3 Months19.4220.136.6610.06385,774-12.46-64.16%
6 Months23.0424.276.6613.30254,575-16.08-69.79%
1 Year49.2059.56996.6620.49212,533-42.24-85.85%
3 Years18.6160.51626.6623.86217,866-11.65-62.6%
5 Years18.6160.51626.6623.86217,866-11.65-62.6%

Shattuck Labs Description

Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. The company's product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.

Your Recent History
Shattuck L..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.